Core Insights - Molecular Partners AG is advancing its Radio-DARPin candidates, which are designed for targeted alpha therapy, and will present new preclinical data at the 3rd Global Radiopharmaceuticals Development Summit in Shanghai on March 19-20, 2026 [1][2] Group 1: Radio-DARPin Candidates - The presentation will highlight the suitability of Radio-DARPin candidates for different isotopes, showcasing two candidates with comparable biodistribution profiles when labeled with Lutetium-177 (Lu) or Lead-203 (Pb) [2] - Studies in tumor-bearing mice indicate similar uptake and washout rates for both Radio-DARPin candidates, suggesting that imaging with Lu can predict behavior with the therapeutic isotope Actinium-225 (Ac) [2] Group 2: Development Flexibility - The CEO of Molecular Partners stated that the Radio-DARPin design allows for the interchangeability of alpha-isotopes, providing flexibility to evaluate candidates in an isotope-agnostic manner [3] - This feature enables the selection of the most suitable therapeutic isotope based on initial clinical data without restarting the entire drug discovery process, which is a significant advantage for tailoring treatments to patient needs [3] Group 3: Clinical Trials and Collaborations - The DLL3-targeted Pb-based Radio-DARPin candidate MP0712 is currently in a Phase 1/2a trial in the US, with imaging data supporting its clinical development for small cell lung cancer and other DLL3-expressing neuroendocrine cancers [5] - In February 2026, Molecular Partners entered into an agreement with Eckert & Ziegler to support the development and manufacturing of Radio-DARPin therapeutics, covering activities for Radio-DARPins with Ac as the therapeutic payload and Lu as the imaging payload [6] Group 4: Technology and Innovation - Molecular Partners' Radio-DARPins are designed to deliver potent alpha-emitting isotopes to tumor lesions, addressing limitations of traditional radioligand therapy such as kidney accumulation and toxicity [7] - The proprietary Radio-DARPin platform enhances the delivery of radioactive payloads while preserving the advantages of small protein formats, thus unlocking a broad range of tumor targets for targeted radiopharmaceuticals [7] Group 5: Company Overview - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics for medical challenges that other treatment modalities cannot address, with proprietary programs in various stages of development [10]

Core Insights - Molecular Partners AG is advancing its Radio-DARPin candidates, which are designed for targeted alpha therapy, and will present new preclinical data at the 3rd Global Radiopharmaceuticals Development Summit in Shanghai [1][4] Group 1: Radio-DARPin Candidates - The presentation will highlight the suitability of Radio-DARPin candidates for different isotopes, showcasing two candidates with comparable biodistribution profiles when labeled with Lutetium-177 (177Lu) and Lead-203 (203Pb) [2] - Studies in tumor-bearing mice indicate similar uptake and washout rates for both Radio-DARPin candidates, suggesting that imaging with 177Lu can predict behavior with the therapeutic isotope Actinium-225 (225Ac) and similarly for 203Pb with 212Pb [2] Group 2: Development Flexibility - The CEO of Molecular Partners stated that the Radio-DARPin design allows for the interchangeability of alpha-isotopes, providing flexibility to evaluate candidates in an isotope-agnostic manner, which can be tailored to patient needs without restarting the drug development process [3] Group 3: Clinical Trials and Partnerships - The MP0712 candidate, which targets DLL3 and is co-developed with Orano Med, is currently in a Phase 1/2a trial in the US, with imaging data supporting its clinical development for small cell lung cancer and other DLL3-expressing neuroendocrine cancers [5] - In February 2026, Molecular Partners entered an agreement with Eckert & Ziegler to support the development and manufacturing of Radio-DARPin therapeutics, focusing on 225Ac as a therapeutic payload and 177Lu as an imaging payload [6] Group 4: Technology and Innovation - Molecular Partners' Radio-DARPins are designed to deliver potent alpha-emitting isotopes precisely to tumor lesions, addressing limitations of traditional radioligand therapy, such as kidney accumulation and toxicity [7] - The proprietary Radio-DARPin platform enhances the delivery of radioactive payloads while minimizing harm to healthy tissues, leveraging the unique properties of DARPins [9] Group 5: Company Overview - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics for challenging medical conditions, with proprietary programs in various stages of development and partnerships with leading pharmaceutical companies [10]

Core Insights - Molecular Partners AG has entered into a partnership with Eckert & Ziegler to advance its Radio-DARPin therapeutics pipeline, focusing on imaging and therapeutic radio-isotopes, including Actinium-225 [1][2] Group 1: Partnership and Development - The agreement with Eckert & Ziegler will enhance the potential of Radio-DARPins for precise delivery of therapeutic alpha-emitting isotopes to tumors, including Actinium-225 and Lead-212 [2][3] - Eckert & Ziegler will provide a comprehensive range of services for the development of Radio-DARPins with Actinium-225 and Lutetium-177 payloads, utilizing its advanced laboratories [3] Group 2: Pipeline and Research - Molecular Partners is evaluating various radio-nuclides to tailor Radio-DARPin candidates to patient needs, aiming to match vector and isotope properties with target and disease biology [4] - The company plans to present pre-clinical data on the suitability of Radio-DARPins with multiple isotopes at the Global Radiopharmaceuticals Development Summit in March 2026 [4] Group 3: Technology and Innovation - Radio-DARPins are designed to deliver potent alpha-emitting isotopes to tumor lesions while minimizing toxicity to healthy tissues, addressing historical limitations of radioligand therapy [6][7] - The proprietary Radio-DARPin platform incorporates half-life extension technologies and surface engineering approaches to enhance therapeutic efficacy [6][7] Group 4: Company Overview - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics for medical challenges that other treatment modalities cannot address [9] - The company has proprietary programs in various stages of pre-clinical and clinical development, alongside partnerships with leading pharmaceutical companies and academic centers [9]

Core Insights - Molecular Partners AG has presented promising first patient imaging and dosimetry data for its DLL3-targeted Radio-DARPin candidate MP0712 at the 8th Theranostics World Congress, indicating strong potential for treating small cell lung cancer and other DLL3-expressing neuroendocrine cancers [1][2][4] Group 1: Clinical Development - The data from five evaluable patients support the clinical development plans for MP0712, which utilizes the therapeutic isotope 212Pb [2][4] - The biodistribution of MP0712 shows specific tumor uptake with limited accumulation in healthy tissues, reinforcing its therapeutic potential [3][4] - The ongoing Phase 1/2a study in the U.S. aims to assess safety and determine a recommended phase 2 dose for MP0712, with initial clinical data expected in 2026 [4][5] Group 2: Presentation Details - The data was presented through two posters and an oral presentation at the Theranostics World Congress, highlighting the favorable distribution profile and dosimetry data of MP0712 [2][5] - An oral presentation titled "From DARPins to Radio-DARPin Therapeutics" was conducted, showcasing the progress of MP0712 [7] Group 3: Company Strategy and Future Outlook - The CEO of Molecular Partners expressed optimism about the data, emphasizing the company's ambition to lead in alpha-targeted therapies for small cell lung cancer and neuroendocrine malignancies [4] - The company plans to share initial Phase 1 safety and activity data in 2026 as it advances its Radio-DARPin platform [4][5] - Molecular Partners' Radio-DARPins are designed to address limitations of traditional radioligand therapy, enhancing tumor uptake while minimizing toxicity [9][10]

Core Insights - Molecular Partners AG is presenting updated data from a Phase 1/2a trial of its T-cell engager MP0533 for treating acute myeloid leukemia (AML) at the 67th ASH Annual Meeting [1][2] Group 1: Trial Results - The multicenter, open-label study shows that densified dosing of MP0533 is tolerable and leads to improved serum exposure with preliminary antitumor activity [2][4] - As of September 1, 2025, 54 patients have been treated with MP0533, with 8 out of 48 evaluable patients achieving a response, including 5 reaching composite complete responses [4] - The trial indicates that patients with lower disease burden are more likely to benefit from MP0533, with 6 of 8 responders presenting with less than 20% bone marrow blasts at baseline [4][7] Group 2: Expert Commentary - Prof. Courtney DiNardo expressed optimism about the clinical benefits of MP0533 in a mutation-agnostic manner for R/R AML patients, particularly those with lower disease burden [3] - Philippe Legenne highlighted the progress of the trial, noting the feasibility of the densified dosing regimen and the interest from consortia for further studies [5] Group 3: Mechanism of Action - MP0533 is a novel tetra-specific T cell-engaging DARPin that targets three tumor-associated antigens (CD33, CD123, CD70) on AML cells and the immune activator CD3 on T cells, designed to preferentially kill AML cells while minimizing damage to healthy cells [6] Group 4: Presentation Details - The poster presentation titled "Phase 1/2 study of MP0533" outlines clinical benefits with an acceptable safety profile across 9 dosing regimens, emphasizing the feasibility of accelerated step-up dosing [7][8]

Core Viewpoint - Molecular Partners AG is advancing its clinical-stage development of MP0533, a novel tetra-specific T cell engager for treating acute myeloid leukemia (AML), with updated data to be presented at the upcoming ASH Annual Meeting [1][2]. Group 1: Clinical Trial Details - The Phase 1/2a trial of MP0533 is a first-in-human, multicenter, open-label study focusing on relapsed/refractory AML and myelodysplastic syndrome (MDS)/AML patients [2]. - Initial results indicate that MP0533 has an acceptable safety profile across dosing regimens DR 1–9, with encouraging preliminary signs of antitumor activity [2]. - The study is currently in the dosing phase for patients in DR 10 [2]. Group 2: Mechanism of Action - MP0533 is designed to engage T cells by targeting three tumor-associated antigens (CD33, CD123, and CD70) on AML cells, as well as the immune activator CD3 on T cells [3]. - This tetra-specific approach allows MP0533 to preferentially bind to AML cells, which commonly express multiple target antigens, while minimizing binding to healthy cells [3]. Group 3: Presentation Details - The presentation at the ASH Annual Meeting will include initial results from the optimized treatment regimen of MP0533, including densified dosing and adapted premedication [4]. - The session is scheduled for December 7, 2025, from 6:00–8:00 PM ET, with the full abstracts available on the ASH website [4]. Group 4: About DARPin Therapeutics - DARPin therapeutics represent a new class of custom-built protein drugs that offer multi-target specificity and high stability, providing advantages over traditional protein-based therapeutics [5]. - The DARPin platform is designed for rapid and cost-effective drug discovery, producing candidates with optimized properties and high production yields [5]. Group 5: Company Overview - Molecular Partners AG focuses on developing DARPin therapeutics to address medical challenges that other drug modalities cannot effectively target, with oncology as its primary area of focus [6]. - The company has been operational since 2004 and maintains offices in Zurich, Switzerland, and Concord, Massachusetts, USA [6].